Exhibit 107

 

Calculation of Filing Fee Tables

 

Form S-8

(Form Type)

 

IceCure Medical Ltd.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities

 

    Security Type   Security Class Title     Fee Calculation     Amount
Registered(1)
    Proposed Maximum Offering Price Per Share     Proposed Maximum Aggregate Offering Price     Fee Rate     Amount of Registration Fee  
Newly Registered Securities
Fees to Be Paid   Equity     Ordinary shares, no par value       457(h)       30,434(2)       $2.73(3)     $ 83,084.82     $ 0.0000927     $ 7.70  
    Equity     Ordinary shares, no par value       457(c)       870,000(4)       $2.60(5)     $ 2,262,000     $ 0.0000927     $ 209.69  
    Total Offering Amounts                                $ 2,345,084.82             $ 217.39  
    Total Fees Previously Paid                                  
    Total Fee Offsets                                  
    Net Fee Due                                  

 

(1)Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, or the Securities Act, this Registration Statement also covers an indeterminate number of additional securities which may be offered and issued to prevent dilution resulting from stock splits, stock dividends, recapitalizations or similar transactions.
(2) Represents additional ordinary shares issuable upon exercise of awards granted under the IceCure 2006 Employee Share Option Plan, as amended from time to time (the “Plan”).
(3) Estimated in accordance with Rule 457(h) under the Securities Act solely for the purpose of calculating the registration fee based upon the exercise price of the option awards for such ordinary shares issuable under the Plan.
(4) Represents the additional ordinary shares reserved for future issuance under the Plan.
(5) Estimated in accordance with Rule 457(c) under the Securities Act, based upon the average of the high and low sales prices of the registrant’s ordinary shares as reported on the Nasdaq Capital Market on April 25, 2022.